Bienvenidos
El grupo BCLC del Hospital Clínico de Barcelona es un equipo multidisciplinar que engloba todas las especialidades médicas relevantes dedicadas a la práctica clínica, investigación y educación en el campo del cáncer hepático. Combina diagnóstico y terapias de última generación con el desarrollo de diferentes proyectos de investigación para valorar nuevas opciones de tratamiento. Éstos incluyen estudios en laboratorio con cultivos celulares o modelos animales y ensayos clínicos en pacientes con cáncer de hígado.
Últimas noticias
Publicaciones recientes
JOURNAL ARTICLE
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Nature 2024;10.1038/s41586-024-08305-z
Pubmed abstract
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Nature 2024;10.1038/s41586-024-08305-z
Pubmed abstract
JOURNAL ARTICLE
Genome-wide DNA methylation markers associated with metabolic liver cancer. Antwi SO, Siaw ADJ, Armasu SM, Frank JA, Yan IK, Ahmed FY, Izquierdo-Sanchez L, Boix L, Rojasti A, Banales JM, Reig M, Stål P, Romero Gómez M, Wangensteen KJ, Singal AG, Roberts LR, Patel T. medRxiv . 2024;10.1101/2024.11.15.24317378.
Pubmed abstract
Genome-wide DNA methylation markers associated with metabolic liver cancer. Antwi SO, Siaw ADJ, Armasu SM, Frank JA, Yan IK, Ahmed FY, Izquierdo-Sanchez L, Boix L, Rojasti A, Banales JM, Reig M, Stål P, Romero Gómez M, Wangensteen KJ, Singal AG, Roberts LR, Patel T. medRxiv . 2024;10.1101/2024.11.15.24317378.
Pubmed abstract
JOURNAL ARTICLE
Utilizing a domain-specific large language model for LI-RADS v2018 categorization of free-text MRI reports: a feasibility study. Matute-González M, Darnell A, Comas-Cufí M, Pazó J, Soler A, Saborido B, Mauro E, Turnes J, Forner A, Reig M, Rimola J.Insights Imaging. 2024;10.1186/s13244-024-01850-1.
Pubmed abstract
Utilizing a domain-specific large language model for LI-RADS v2018 categorization of free-text MRI reports: a feasibility study. Matute-González M, Darnell A, Comas-Cufí M, Pazó J, Soler A, Saborido B, Mauro E, Turnes J, Forner A, Reig M, Rimola J.Insights Imaging. 2024;10.1186/s13244-024-01850-1.
Pubmed abstract
JOURNAL ARTICLE
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death. Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C.Clin Cancer Res. 2024;10.1158/1078-0432.CCR-24-2582.
Pubmed abstract
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death. Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, Ciccia R, Manfredi GF, Iavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Cammà C.Clin Cancer Res. 2024;10.1158/1078-0432.CCR-24-2582.
Pubmed abstract
JOURNAL ARTICLE
Rare primary liver cancers: An EASL position paper. Wege H, Campani C, de Kleine R, Meyer T, Nault JC, Pawlik TM, Reig M, Ricke J, Sempoux C, Torzilli G, Zucman-Rossi J.J Hepatol. 2024;10.1016/j.jhep.2024.06.004.
Pubmed abstract
Rare primary liver cancers: An EASL position paper. Wege H, Campani C, de Kleine R, Meyer T, Nault JC, Pawlik TM, Reig M, Ricke J, Sempoux C, Torzilli G, Zucman-Rossi J.J Hepatol. 2024;10.1016/j.jhep.2024.06.004.
Pubmed abstract
JOURNAL ARTICLE
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL.J Hepatol. 2024;10.1016/j.jhep.2024.07.017
Pubmed abstract
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL.J Hepatol. 2024;10.1016/j.jhep.2024.07.017
Pubmed abstract
JOURNAL ARTICLE
Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Ríos J, Sapena V, Mariño Z, Bruix J, Forns X, Morros R, Reig M, Torres F, Pontes C. Drugs Real World Outcomes. 2024;10.1007/s40801-024-00437-y.
Pubmed abstract
Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Ríos J, Sapena V, Mariño Z, Bruix J, Forns X, Morros R, Reig M, Torres F, Pontes C. Drugs Real World Outcomes. 2024;10.1007/s40801-024-00437-y.
Pubmed abstract
JOURNAL ARTICLE
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH. Grøndal SM, Tutusaus A, Boix L, Reig M, Blø M, Hodneland L, Gausdal G, Jackson A, Garcia de Frutos P, Lorens JB, Morales A, Marí M. Front Immunol. 2024;10.3389/fimmu.2024.1400553.
Pubmed abstract
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH. Grøndal SM, Tutusaus A, Boix L, Reig M, Blø M, Hodneland L, Gausdal G, Jackson A, Garcia de Frutos P, Lorens JB, Morales A, Marí M. Front Immunol. 2024;10.3389/fimmu.2024.1400553.
Pubmed abstract